HDL-C in Cardiac Syndrome X

HDL-Cholesterol is Inversely Related With Inflammation in Cardiac Syndrome X

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02095964

Acronym

HIRICS-X

Enrollment

710

Registered

2014-03-26

Start date

2012-03-31

Completion date

2014-01-31

Last updated

2014-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Diseases, Heart Diseases, Microvascular Angina, Myocardial Ischaemia, Unstable Angina

Keywords

cardiac syndrome X, inflammation, dyslipidemia

Brief summary

High density lipoprotein cholesterol (HDL-C) is in the centrum of the process of reverse cholesterol transport from peripheral cells to the liver\[10\]. HDL-C promotes endothelial generation of nitric oxide (NO) and improves endothelial function and arterial vasoreactivity\[11\]. In several studies, lower HDL-C level was reported to be associated with increased coronary artery disease (CAD) risk\[12-14\]. HDL-C also has anti- inflammatory and anti-oxidant activities\[15,16\]. Concerning anti-inflammatory activity, HDL-C inhibits the activation of monocytes/macrophages and neutrophils\[17,18\] and inhibits the expression of endothelial adhesion molecules, such as vascular cell adhesion molecule-1 (VCAM-1) and E-selectin\[15\]. In this study we aimed to investigate the relation of HDL-C level with systemic inflammatory markers in patients with cardiac syndrome X (CSX).

Interventions

None listed

Study design

Observational model

CASE_CROSSOVER

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

47 Years to 58 Years

Healthy volunteers

Yes

Inclusion criteria

* Must be able to get exercise stress test * Must be able to have coronary angiography * Clinical diagnosis of typical anginaduring rest or effort * Abnormal test result for exercise ECG or myocardial perfusion scintigraphy * Must have of angiographically normal epicardial coronary arteries

Exclusion criteria

* Patients with valvular heart disease (mitral stenosis and moderate to severe mitral regurgitation * Patients with moderate to severe aortic stenosis and regurgitation including mitral annular calcification) * Patients with heart failure (left ventricular ejection fraction \<50%) * Patients with congenital heart disease, cardiomyopathy, left ventricular hypertrophy, right ventricular hypertrophy * Patients with cardiac surgery * Patients with thyroid disease * Patients with anemia * Patients with pulmonary diseases * Patients with infectious diseases (locally or systemic)

Design outcomes

Primary

Measure	Time frame	Description
HDL-Cholesterol	6 MONTHS	HDL-Cholesterol \<40 mg/dL(male) / \< 50mg/dL(female) ==\> low HDL-C
Cardiac Syndrome X	6 months	Patients who have typical anginal chest pain+ischaemic findings at exercise stress test/myocardial scintigraphy + normal epicardial coronaries at coronary angiography ==\> Cardiac syndrome X
Inflammation	6 months	CRP \> 2,98 mg/dL ==\> systemic inflammation

Outcome results